This dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist helps in managing both T2DM and obesity by leveraging its dual-action mechanism, which has been associated with improvements in weight reduction and glycemic control [4]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.